Targeting a specific protein to reduce inflammation in bowel disease
Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity
This study is testing a new treatment called ALT-100, which is designed to help people with inflammatory bowel disease (IBD) by targeting a protein that makes inflammation worse, with the hope of reducing symptoms and improving bowel health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aqualung Therapeutics Corp. NIH-funded |
| Lab location | 1 site (Juno Beach, UNITED STATES) |
| Project ID | NIH-10907806 on NIH RePORTER |
What this research studies
This research investigates the use of a novel humanized monoclonal antibody called ALT-100, which aims to neutralize a protein known as eNAMPT that plays a significant role in activating inflammatory pathways in inflammatory bowel disease (IBD). By targeting this protein, the research seeks to limit bowel injury and fibrosis, potentially reducing the severity of IBD symptoms. The approach is based on evidence showing that eNAMPT levels are elevated in IBD patients and correlate with disease severity. Patients may be monitored for changes in inflammation and overall bowel health as part of the research.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease who experience significant symptoms and have not responded adequately to existing treatments.
Not a fit: Patients with mild IBD symptoms or those who have not been diagnosed with inflammatory bowel disease may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from inflammatory bowel disease, potentially improving their quality of life.
How similar studies have performed: Previous research has shown promising results in targeting eNAMPT for inflammatory conditions, suggesting that this approach may be effective in treating IBD as well.
Where this research is happening
Juno Beach, UNITED STATES
- Aqualung Therapeutics Corp. — Juno Beach, United States (Active)
Researchers
- Principal investigator: Garcia, Joe G. N. — Aqualung Therapeutics Corp.
- Study coordinator: Garcia, Joe G. N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.